Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Our findings indicate that continuous administration of CCFM1126 for 3 months resulted in a significant increase in serum vitamin D levels (Wilcoxon paired test, p = 0.0040) and OPG content (Wilcoxon paired test, p = 0.0206) in OP patients relative to baseline.

Source: Effects of L. fermentum CCFM1126 on physiological and biochemical indexes in OP patients. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Double-blind reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Limosilactobacillus fermentum CCFM1126 attenuates osteoporosis by modulating the gut microbiota composition and fecal metabolites: A randomized, double-blind, placebo-controlled clinical trial

Source: Article title.

Limosilactobacillus fermentum CCFM1126 attenuates osteoporosis by modulating the gut microbiota composition and fecal metabolites: A randomized, double-blind, placebo-controlled clinical trial

Source: Article title.

Throughout the trial period, participants were required to refrain from using other probiotic products or antibiotics and to maintain consistent dietary habits.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Limosilactobacillus fermentum CCFM1126 attenuates osteoporosis by modulating the gut microbiota composition and fecal metabolites: A randomized, double-blind, placebo-controlled clinical trial

Randomised controlled trial · Gut Microbes Reports · 2026

Original publication title

Limosilactobacillus fermentum CCFM1126 attenuates osteoporosis by modulating the gut microbiota composition and fecal metabolites: A randomized, double-blind, placebo-controlled clinical trial

Yaru Liu; Jiani Pan; Leilei Yu; Chuan Zhang; Chengcheng Zhang; Qingwei Yao; Xingxing Chen; Xuesong Wang; Jianxin Zhao; Fengwei Tian; Qixiao Zhai; Wei Chen

© 2026 The Author(s). Published with license by Taylor & Francis Group, LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

ABSTRACT

Osteoporosis (OP) is a common systemic metabolic bone disorder characterized by reduced bone mass and deteriorated bone microarchitecture. Limosilactobacillus fermentum CCFM1126 has previously been shown to mitigate intestinal barrier dysfunction and modulate bone metabolism, thereby attenuating bone loss in OP rat models. To further evaluate its clinical efficacy, a double-blind, randomized, placebo-controlled trial was conducted. Additionally, the optimal intervention dose and potential bioactive components were investigated using ovariectomized (OVX) rat models and MC3T3-E1 pre-osteoblast cell assays. In the clinical trial, CCFM1126 supplementation significantly increased bone mineral density (BMD), elevated serum calcium and 25-hydroxyvitamin D levels, and reshaped gut microbiota composition by reducing the relative abundances of Paraprevotella, Marvinbryantia, Ruminococcus 1, and Granulicatella.

In OVX rats, a dose of 10⁷ CFU/mL exerted minimal effects on bone morphology and metabolism, whereas doses ≥ 10⁸ CFU/mL led to significant improvements in bone structure and systemic metabolic indices, accompanied by favorable modulation of the gut microbial profile. The most pronounced effects were observed at 10⁹ CFU/mL. In MC3T3-E1 pre-osteoblasts, metabolites derived from CCFM1126 enhanced cell viability and upregulated the expression of key osteogenic genes. Among these, choline was identified as a potential bioactive compound contributing to the anti-osteoporotic effects of CCFM1126.

Authors’ abstract

ABSTRACT

Osteoporosis (OP) is a common systemic metabolic bone disorder characterized by reduced bone mass and deteriorated bone microarchitecture. Limosilactobacillus fermentum CCFM1126 has previously been shown to mitigate intestinal barrier dysfunction and modulate bone metabolism, thereby attenuating bone loss in OP rat models. To further evaluate its clinical efficacy, a double-blind, randomized, placebo-controlled trial was conducted. Additionally, the optimal intervention dose and potential bioactive components were investigated using ovariectomized (OVX) rat models and MC3T3-E1 pre-osteoblast cell assays. In the clinical trial, CCFM1126 supplementation significantly increased bone mineral density (BMD), elevated serum calcium and 25-hydroxyvitamin D levels, and reshaped gut microbiota composition by reducing the relative abundances of Paraprevotella, Marvinbryantia, Ruminococcus 1, and Granulicatella.

In OVX rats, a dose of 10⁷ CFU/mL exerted minimal effects on bone morphology and metabolism, whereas doses ≥ 10⁸ CFU/mL led to significant improvements in bone structure and systemic metabolic indices, accompanied by favorable modulation of the gut microbial profile. The most pronounced effects were observed at 10⁹ CFU/mL. In MC3T3-E1 pre-osteoblasts, metabolites derived from CCFM1126 enhanced cell viability and upregulated the expression of key osteogenic genes. Among these, choline was identified as a potential bioactive compound contributing to the anti-osteoporotic effects of CCFM1126.

Publication and source details

Original title: Limosilactobacillus fermentum CCFM1126 attenuates osteoporosis by modulating the gut microbiota composition and fecal metabolites: A randomized, double-blind, placebo-controlled clinical trial

Yaru Liu; Jiani Pan; Leilei Yu; Chuan Zhang; Chengcheng Zhang; Qingwei Yao; Xingxing Chen; Xuesong Wang; Jianxin Zhao; Fengwei Tian; Qixiao Zhai; Wei Chen

Gut Microbes Reports · 2026

CONTACT Leilei Yu edyulei@126.com Wuxi Institute for Specialized Nutrition and Health, Co., Ltd., Wuxi, Jiangsu 214028, China; Xuesong Wang 15951581217@163.com Department of Orthopedics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214122, China
1

Yaru Liu and Jiani Pan contributed equally.

© 2026 The Author(s). Published with license by Taylor & Francis Group, LLC.2026The Author(s)https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:31:11.647226+00:00

DOI: 10.1080/29933935.2026.2669712 · PMC13182971